Tiziana Life Sciences Publishes Positive Foralumab Clinical Data in Peer-Reviewed Neurology Journal
TLSA has more than doubled off its 52-week low of $0.63.
Summary
Tiziana Life Sciences announced the peer-reviewed publication of positive clinical study results for intranasal foralumab in patients with non-active secondary progressive multiple sclerosis, validating its therapeutic potential.
Key Events · Product Development and Regulatory · TLSA
-
Peer-Reviewed Publication
Clinical study results for intranasal foralumab in non-active secondary progressive multiple sclerosis (na-SPMS) were published in "Neurology Neuroimmunology & Neuroinflammation," a prestigious journal of the American Academy of Neurology.
-
Positive Clinical Outcomes
The open-label study involving ten na-SPMS patients showed stabilization of Expanded Disability Status Scale (EDSS) scores in all patients, with three of four treated for 12 months demonstrating improvement. Fatigue also improved in six out of ten patients.
-
Biomarker Validation
The study revealed significant reductions in microglial activation via TSPO-PET imaging and sustained increases in regulatory T cells (Tregs) and TGFβ expression, supporting the drug's novel mechanism of action.
-
Ongoing Phase 2 Trial
Tiziana is advancing intranasal foralumab in a randomized, double-blind, placebo-controlled Phase 2 trial in na-SPMS, with top-line data anticipated in the first half of 2026.
Analysis · TLSA · Life Sciences
The peer-reviewed publication of clinical study results for intranasal foralumab in a prestigious neurology journal provides significant scientific validation for the company's lead candidate. The study demonstrated stabilization of disability, improvement in fatigue, and reduction in neuroinflammation, suggesting a novel mechanism of action. This publication strengthens the scientific credibility of foralumab and supports the ongoing Phase 2 trial, which is expected to report top-line data in the first half of 2026. Investors should monitor the progress of the Phase 2 trial for further clinical advancements.
At the time of this filing, TLSA was trading at $1.70 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $201.5M. The 52-week trading range was $0.63 to $2.60. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.